Clinical Trial Update: A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa [Phase 2]

View source ↗

Summary

Kiora Pharmaceuticals is conducting a Phase II intravitreal study of KIO-301 in late-stage retinitis pigmentosa and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• KIO-301 (KIO-301)

Snippet

Sponsor: Kiora Pharmaceuticals, Inc. | Conditions: Retinitis Pigmentosa | Phase 2 | Status: RECRUITING